Clarity begins trial for pediatric neuroblastoma therapy

By staff writers

July 23, 2020 -- Radiopharmaceutical firm Clarity Pharmaceuticals has begun recruitment for a phase I/IIA clinical trial evaluating its SARTATE peptide receptor radionuclide therapy for pediatric patients with neuroblastoma.

The open label, dose-escalation trial will administer Cu-67 SARTATE to pediatric patients with high-risk neuroblastoma at Memorial Sloan Kettering Cancer Center in New York.

Neuroblastoma is the most common type of cancer to be diagnosed in children under the age of 1 and accounts for 15% of pediatric cancer deaths. The five-year survival rate for children with high-risk neuroblastoma is only 40%-50%, the researchers noted.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking